A Devex event in partnership with Gilead

Access to medicines:

Sustainable delivery models that leave no one behind

September 23, 2021 — 12 p.m. ET | 6 p.m. CET


Hosted by:


In partnership with:


About the Event

Nearly 2 billion of the world’s population living in low- and middle-income countries still do not have access to basic medicines, according to the World Health Organization. But COVID-19 can offer a valuable lesson in how the global health community can jointly improve access to life-saving medicines for the most underserved populations.

Innovative medicines and treatments emerging from research and development pipelines are revolutionizing health in various areas, yet many people still lack access to well-known essential medicines. In the context of the current pandemic, we have the opportunity to not only fast-track access to new products, but also ensure everyone, everywhere, can afford them.

On Thursday, Sept. 23, Devex will host an ecosystem event on the sidelines of the 76th annual United Nations General Assembly in partnership with Gilead, exploring how new access models can allow for more coordinated and targeted approaches. Discussions will draw on lessons learned from the pandemic and beyond on how to best support more resilient health systems, and ultimately ensure progress on universal health coverage and the health-related Sustainable Development Goals.

This event will include live captioning.

UHC Pavilion

Save your Spot on Thursday, September 23 at 12 p.m. ET | 6 p.m. CET


12:00 p.m. ET

Welcome & introduction by Amruta Byatnal, Associate Editor, Devex

12:05 p.m. ET

Fireside chat: Delivering medicines in a pandemic


• Farhan Yusuf, Pharmacist, Health Supply Chain Professional and Youth Advocate

• Amruta Byatnal, Associate Editor, Devex

12:15 p.m. ET

Panel Discussion


• Osman Khalid Waheed, CEO, Ferozsons
• Dr. Harald Nusser, Head, Global Patient Solutions, Gilead

• Amruta Byatnal, Associate Editor, Devex

12:55 p.m. ET

Closing Remarks by Amruta Byatnal, Associate Editor, Devex


Farhan Yusuf

Farhan Yusuf

Pharmacist, Health Supply Chain Professional and Youth Advocate

Farhan Yusuf is a Pharmacist practicing as a Health Supply Chain Professional and Youth Advocate. He has worked across the public, private and NGO sector in Tanzania developing expertise in health logistics & pharmaceutical supply chain management, public private partnership, capacity building, program management, monitoring and evaluation, communications and knowledge management over the last 10 years. He served as a Senior Program Officer on the USAID-funded SHOPS Plus project and a volunteer for the Youth Leaders for Health Program.

Amruta Byatnal

Amruta Byatnal

Associate Editor, Devex

Amruta Byatnal is an Associate Editor at Devex based in New Delhi. She reports on global health, gender and human rights. Previously, she worked for News Deeply and The Hindu. She is a graduate of Cornell University where she studied international development.

Harald Nusser

Harald Nusser

Vice President, Global Patient Solutions, Gilead Sciences

Harald Nusser is heading Global Patient Solutions at Gilead Sciences, a team which is responsible for the leadership of the Gilead portfolio in more than 120 countries in Central America & Caribbean, Eastern Europe & Central Asia, Africa as well as India & South East Asia. Access to and affordability of medicines is a priority for this unit. Besides, Harald is a Global Ambassador of the G20 Health & Development Partnership. Until spring 2021, Harald led Novartis Social Business. In that capacity he was recognized by the Schwab Foundation for Social Entrepreneurship as a Corporate Social Intrapreneur of the Year 2019. Harald served on the Board of the UNITAR hosted Defeat-NCD Partnership in its inaugural year. Prior to his engagement with Novartis, he has been leading the Bayer Healthcare Business in 48 LMICs in Asia, Sub-Saharan Africa and Latin America. Harald holds a PhD in Mathematics of the Free University of Berlin and an Executive MBA from Bradford University, UK.

Osman Khalid Waheed

Osman Khalid Waheed

CEO, Ferozsons

Osman Khalid Waheed joined Ferozsons Laboratories Limited, a publicly listed pharmaceutical company in 1993 after obtaining his undergraduate degree from Harvard. During his tenure as CEO since 1998, the company has forged alliances with international partners including the Boston Scientific Corporation and Gilead Sciences Inc. to expand access in disease areas including heart disease, viral hepatitis, HIV and Covid-19. In 2019, Ferozsons became one of 9 international producers selected to manufacture and supply its therapeutic remdesivir to 127 low and middle-income countries under a voluntary license from Gilead. Mr. Waheed serves as a trustee of LUMS, Pakistan’s premier multi-disciplinary university, and was the founding chairman of the Lahore Biennale Foundation, a non-profit dedicated to public art. Mr. Waheed has previously served on the board of the Trade Development Authority of Pakistan (TDAP), Pakistan Industrial Development Corporation (PIDC), and as president of the Rawalpindi Chamber of Commerce. He currently serves on the Board of Directors of the Murree Brewery Company Limited and DGS (Pvt) Limited.